The Impact of Ascidian (Halocynthia roretzi)-derived Plasmalogen on Cognitive Function in Healthy Humans: A Randomized, Double-blind, Placebo-controlled Trial.

OBJECTIVES: Plasmalogen, phospholipids with previously shown associations with dementia, has attracted attention as a substance found in some studies to improve cognitive function. The effects of ascidian-derived plasmalogens on cognitive performance improvement were assessed in a randomized, double-blind, placebo-controlled study including Japanese adult volunteers with mild forgetfulness. METHODS: Participants consumed either the active food containing ascidian-derived plasmalogen (1 mg as plasmalogen) or the placebo food for 12 weeks, and their cognitive performance was assessed by Cognitrax. Participants were randomly allocated into the intervention (ascidian-derived plasmalogen; 8 males, and 17 females; 45.6 ± 11.1 years) or the placebo (9 males, and 15 females; mean age, 46.4 ± 10.8 years) group. RESULTS: Compared to the placebo group, the intervention group showed a significant increase score in composite memory (eight weeks: 3.0 ± 16.3 points, 12 weeks: 6.7 ± 17.5 points), which was defined as the sum of verbal and visual memory scores. CONCLUSIONS: These results indicate the consumption of ascidian-derived plasmalogen maintains and enhances memory function. This study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN-CTR, registry no. UMIN000026297). This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Evaluation of Biological Activity of Mastic Extracts Based on Chemotherapeutic Indices.

BACKGROUND: Most previous mastic investigators have not considered its potent cytotoxicity that may significantly affect the interpretation of obtained data. In the present study, we re-evaluated several biological activities of mastic extracts, based on chemotherapeutic indexes. MATERIALS AND METHODS: Pulverized mastic gum was extracted with n-hexane and then with ethyl acetate or independently with methanol or n-butanol. Tumor specificity (TS) of the extracts was determined by their cytotoxicity against human malignant and non-malignant cells. Antibacterial activity was determined by their cytotoxicity against bacteria and normal oral cells. Antiviral activity was determined by their protection of viral infection and cytotoxic activity. Cytochrome P-450 (CYP) 3A4 activity was measured by ß-hydroxylation of testosterone. RESULTS: Ethyl acetate extract showed slightly higher tumor specificity (TS=2.6) and one order higher antibacterial activity (selectivity index (SI)=0.813) than other extracts (TS=1.4-2.5; SI=0.030-0.063). All extracts showed no anti-human immunodeficiency virus (HIV) activity, but some anti-herpes simplex virus (HSV) activity, which was masked by potent cytotoxicity. They showed strong inhibitory activity against CYP3A4. CONCLUSION: Ethyl acetate extraction following the removal of cytotoxic and CYP3A4 inhibitory substances by n-hexane can enhance antitumor and antibacterial activity of mastic.

Effect of liquid crystals with cyclodextrin on the bioavailability of a poorly water-soluble compound, diosgenin, after its oral administration to rats.

Diosgenin, found in wild yam (Dioscorea villosa), has been shown to ameliorate diabetes and hyperlipidemia, increase cell proliferation in a human 3D skin model, and inhibits melanin production in B16 melanoma cells. It is also an active element in cosmeceutical and dietary supplements. Although the bioavailability of diosgenin is low due to its poor solubility and intestinal permeability, it was subsequently improved using a ß-cyclodextrin (ß-CD) inclusion complex. Recently liquid crystals (LCs) were shown to enhance the bioavailability of poorly water-soluble drugs. The purpose in the present study was to prepare diosgenin LCs and investigate the interaction between LC and ß-CD in order to improve its bioavailability of diosgenin. Crystallinity and particle diameters of LCs in water were determined by small angle X-ray scattering (SAXS) and Zetasizer. Pharmacokinetic parameters were calculated using the plasma content of diosgenin after its oral administration to Wistar rats. Regarding the formation of glyceryl monooleate (GMO) and phytantriol (PHY) LC, SAXS patterns showed the hexagonal and cubic phases, respectively. Bioavailability was significantly enhanced after oral administration of LCs prepared by GMO than after diosgenin alone. The bioavailability was further improved with the combination of LC and ß-CD than LC and water.

Effect of ß-cyclodextrin derivatives on the diosgenin absorption in Caco-2 cell monolayer and rats.

Orally administrated diosgenin, a steroidal saponin found in the roots of Dioscorea villosa, improves reduced skin thickness in ovariectomized mice, and plays an important role in the treatment of hyperlipidemia. Diosgenin has been noticed as an active element in cosmeceutical and dietary supplements. We have already elucidated that the absolute oral bioavailability of diosgenin is very low; however, a high skin distribution of diosgenin was also observed. The aim of the present study was to examine and compare the effects of ß-cyclodextrin (ß-CD) and 3 kinds of its derivatives such as hydroxypropyl ß-CD on the diosgenin permeability using a Caco-2 model and rat jejunal perfusion. These derivatives of ß-CD greatly improved the low solubility of diosgenin. No significant increase was observed in the lactate dehydrogenase leakage from Caco-2 cell, while a slight decrease was found on the transepithelial electrical resistance by diosgenin and ß-CD derivatives. However, ß-CD derivatives, especially hydroxyethyl ß-CD and hydroxypropyl ß-CD, markedly enhanced diosgenin permeability across the Caco-2 monolayer and rat jejunum. The bioavailability of diosgenin in the presence of ß-CD derivatives were about 4 to 11 fold higher than diosgenin suspension. The mechanisms of these enhancement effects may be due to improvements in solubility and tight junction opening.

Enhancement of diosgenin distribution in the skin by cyclodextrin complexation following oral administration.

Orally administrated diosgenin, a steroidal saponin found in several plants including Dioscorea villosa, recovers skin thickness reduced in ovariectomized mice, and plays an important role in the treatment of hyperlipidemia. Thus, diosgenin is an active element of cosmeceutical and dietary supplements. However, we have already elucidated that the skin distribution and absolute oral bioavailability of diosgenin is very low. The aim of this study is to evaluate the efficacy of diosgenin-cyclodextrin (CD) complexes in improving the skin concentration of diosgenin. The formation of the CD complex was indicated by powder X-ray diffraction (XRD), differential scanning calorimetry (DSC), and scanning electron microscope (SEM) studies. Oral administration of the diosgenin/ß-CD complex resulted in a significant enhancement in terms of the skin distribution of diosgenin, maximum plasma level (C(max)), area under the plasma concentration-time curve (AUC), and absolute oral bioavailability over those of the drug alone. These results suggest that the inclusion complex of diosgenin/ß-CD can be used to improve low skin content of diosgenin.

Examination of the expression of cyclooxygenase-2 in placenta villi from sufferers of pregnancy induced hypertension.

OBJECTIVES: The purpose of this paper is to elucidate the roles of phospholipase A(2) (PLA(2)), cyclooxygenase-2 (COX-2), and prostaglandin I(2) (PGI(2)) synthase in pregnancy induced hypertension (PIH). METHODS: In placentas from normal pregnant women and pregnant women with severe PIH, the enzyme expression of PLA(2), COX-2, and PGI(2) synthase was measured using real time reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: The expression of each enzyme was compared between normal (n=12) and PIH (n=12) groups. The expression levels of COX-2 and PGI(2) synthase during PIH pregnancy were significantly decreased to about 51% and 68%, respectively, of their values in normal pregnancy. However, the expression of PLA(2) was hardly changed by PIH. CONCLUSIONS: The decreases in COX-2 and PGI(2) synthase expression in severe PIH placentas may be causal factors in the disruption of the PGI(2)-thromboxane A(2) (TXA(2)) balance in favor of TXA(2). The decrease in COX-2 was more marked than that of PGI(2) synthase.

Presence and some characteristics of peroxisomes in immortalized human trophoblast cells.

Using morphological and biochemical (Western blot and cell fractionation) methods, we investigated whether peroxisomes are present in human extravillous trophoblast cells. Immortalized extravillous trophoblast cells (TCL-1) were incubated in the presence or absence of 0.5 mM clofibric acid for 3 d. In immunofluorescence staining of trophoblast cells with antibodies anti-catalase and anti-acyl-CoA oxidase (marker enzymes of peroxisomes), electron microscopy and immunoelectron microscopy, peroxisomes were detected in the cells. The size and number of peroxisomes in the trophoblast cells were smaller than those in rat liver. The number of peroxisomes was increased by clofibric acid. In Western blot experiment with antibodies anti-peroxisomal enzymes of beta-oxidation system, densitometric analysis revealed approximately two fold increase in staining by clofibric acid. When we performed cell fractionation experiment using catalase as one of the peroxisomal marker enzymes, the highest activity of catalase was found in the light mitochondrial fraction. Specific activity of catalase in the light mitochondrial fraction was significantly increased to about 1.3 times higher than the control value by clofibric acid treatment. Upon Nycodenz density gradient centrifugation, the catalase activity was concentrated in the density fraction around 1.14-1.15. These findings suggest that microperoxisomes, which have a density smaller than those of rat hepatic peroxisomes, do exist in human extravillous trophoblast cells. It may also be possible to proliferate human peroxisomes in limited quantities using peroxisome proliferator of rodents.